Optimizing Treatment Outcomes in Advanced NSCLC with Concurrent Biomarker Testing - Episode 9

Key Takeaways for Concurrent Biomarker Testing in NSCLC

,

Zofia Piotrowska, MD, MHS, and Martin Dietrich, MD, PhD, emphasize the critical role of both tissue and liquid biopsies, the necessity of rapid time-to-treatment initiation, and the increasing likelihood of liquid biopsies becoming the standard of care for metastatic non-small cell lung cancer patients in the near future.